

Agenda: Ontario Steering Committee for Cancer Drugs (OSCCD)

Date: September 28, 2020

Time: 1:00-3:00PM

Time	Topic	Description	Presenter(s)
1:00-1:10	<ul style="list-style-type: none">WelcomeAgenda and ObjectivesCOI DeclarationsMembership Update	Inform members of current status	Interim Chair
1:10-2:10	<p>Daratumumab subcutaneous (SC) in first line and relapsed/refractory multiple myeloma:</p> <ol style="list-style-type: none">Daratumumab SC as part of DRd and DVd for multiple myeloma patients who have received at least one prior therapyDaratumumab SC as part of DRd and DVMP for newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant	Submission	Lead/Clinical Presenter PE Presenter
5 minute BREAK			
2:15-2:55	<ul style="list-style-type: none">NK₁ Receptor Antagonists for carboplatin AUC \geq 5: netupitant/palonosetron (Akynzeo™) and aprepitant (Emend™) criteria change	Request for advice	Clinical/BIA Presenter
2:55-3:00	<ul style="list-style-type: none">Closing remarks<ul style="list-style-type: none">Reminder to shred materialsHousekeeping Items	Inform members	Interim Chair